Lv11
10 积分 2026-01-28 加入
Therapeutic potential of RQ-00311651, a novel T-type Ca2+ channel blocker, in distinct rodent models for neuropathic and visceral pain
7小时前
已完结
How AI agents will change research: a scientist’s guide
3个月前
已完结
Prodrugs as Drug Delivery Systems IV: N-mannich bases as Potential Novel Prodrugs for Amides, Ureides, Amines, and Other NH-acidic Compounds
5个月前
已完结
Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma
5个月前
已完结
Ifupinostat: First Approval
6个月前
已完结
T-type calcium channel blockers: a patent review (2012–2018)
6个月前
已完结
SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial
6个月前
已完结
Fosrolapitant/Palonosetron: First Approval
7个月前
已完结
First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
7个月前
已完结
First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
7个月前
已完结
皖公网安备34019202002308
